CU20200091A7 - Producto inmunógeno que comprende il-4 y/o il-13 - Google Patents

Producto inmunógeno que comprende il-4 y/o il-13

Info

Publication number
CU20200091A7
CU20200091A7 CU2020000091A CU20200091A CU20200091A7 CU 20200091 A7 CU20200091 A7 CU 20200091A7 CU 2020000091 A CU2020000091 A CU 2020000091A CU 20200091 A CU20200091 A CU 20200091A CU 20200091 A7 CU20200091 A7 CU 20200091A7
Authority
CU
Cuba
Prior art keywords
immunogenic product
product including
sub
present
cytokine
Prior art date
Application number
CU2020000091A
Other languages
English (en)
Inventor
Romain Bertrand
Pierre Bruhns
Noémie Caillot
García Eva Conde
Géraldine Grouard-Vogel
Laurent Reber
Vincent Serra
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut, Neovacs filed Critical Inst Nat Sante Rech Med
Publication of CU20200091A7 publication Critical patent/CU20200091A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>La presente invención se refiere a un producto inmunógeno que comprende una citocina conjugada con una proteína portadora, en donde la citocina se selecciona del grupo que comprende IL-4, IL-13 y mezclas de los mismos, y en donde la proteína portadora es CRM<sub>197</sub>. La presente invención se refiere además a un método para elaborar el producto inmunógeno de la invención.</p>
CU2020000091A 2018-05-29 2019-05-29 Producto inmunógeno que comprende il-4 y/o il-13 CU20200091A7 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862677290P 2018-05-29 2018-05-29
EP18305651.4A EP3574915A1 (en) 2018-05-29 2018-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
PCT/EP2019/050154 WO2019228674A1 (en) 2018-05-29 2019-01-04 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il-13 expression or activity
PCT/EP2019/064025 WO2019229153A2 (en) 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Publications (1)

Publication Number Publication Date
CU20200091A7 true CU20200091A7 (es) 2021-07-02

Family

ID=62631036

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000091A CU20200091A7 (es) 2018-05-29 2019-05-29 Producto inmunógeno que comprende il-4 y/o il-13

Country Status (14)

Country Link
US (1) US20210205427A1 (es)
EP (3) EP3574915A1 (es)
JP (2) JP7291729B2 (es)
KR (1) KR20210022571A (es)
CN (1) CN112423784A (es)
AU (1) AU2019276173A1 (es)
BR (1) BR112020024308A2 (es)
CA (1) CA3101702A1 (es)
CU (1) CU20200091A7 (es)
IL (2) IL309932A (es)
MA (1) MA52748A (es)
MX (1) MX2020012925A (es)
SG (1) SG11202011528UA (es)
WO (2) WO2019228674A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
CA3229324A1 (en) * 2021-08-20 2023-02-23 Beatrice DROUET Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646A (en) 1838-03-21 Improvement in furnaces for smelting iron with anthracite
US6207A (en) 1849-03-20 Improved spriing snap-hook
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
BR9914160A (pt) 1998-09-30 2001-06-26 American Cyanamid Co Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante
CN1541111A (zh) 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
JP2006501249A (ja) 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
CN100558747C (zh) * 2006-04-06 2009-11-11 海南天源康泽医药科技有限公司 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用
KR102017905B1 (ko) 2011-04-07 2019-09-03 니오베크스 Ifn 알파 관련 질환을 치료하는 방법
CN103635446B (zh) 2011-05-04 2016-02-03 巴兰斯医疗公司 戊四唑衍生物
CN105693865B (zh) * 2011-06-01 2020-07-17 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PL2668959T3 (pl) 2012-05-31 2015-04-30 Innavirvax Związki immunogenne zawierające peptyd HIV gp41 sprzężony z białkiem nośnikowym CRM197
CA3025648A1 (en) * 2016-05-27 2017-11-30 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
IL278898A (en) 2021-01-31
WO2019229153A3 (en) 2020-02-20
MX2020012925A (es) 2021-08-11
US20210205427A1 (en) 2021-07-08
JP2023110045A (ja) 2023-08-08
EP3574915A1 (en) 2019-12-04
IL309932A (en) 2024-03-01
WO2019228674A1 (en) 2019-12-05
CN112423784A (zh) 2021-02-26
IL278898B2 (en) 2024-06-01
AU2019276173A1 (en) 2020-12-17
BR112020024308A2 (pt) 2021-02-23
JP7291729B2 (ja) 2023-06-15
JP2021525726A (ja) 2021-09-27
IL278898B1 (en) 2024-02-01
CA3101702A1 (en) 2019-12-05
WO2019229153A2 (en) 2019-12-05
KR20210022571A (ko) 2021-03-03
EP4144366A1 (en) 2023-03-08
EP3801603A2 (en) 2021-04-14
SG11202011528UA (en) 2020-12-30
MA52748A (fr) 2021-06-02

Similar Documents

Publication Publication Date Title
UY37563A (es) Aislados de bacillus y usos de los mismos
CO2019009927A2 (es) Isoquinolinas como inhibidores de hpk1
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
UY38476A (es) Inhibidores de arg1 y/o arg2
CL2020002839A1 (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas.
MY195442A (en) Anti-CD40 Antibodies and Their Uses
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2020012060A2 (es) Inhibidores de la arginasa
CU20200091A7 (es) Producto inmunógeno que comprende il-4 y/o il-13
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
AR101202A1 (es) Anticuerpo anti-tie2 humana
AR115599A1 (es) Método y aparato para la preparación de un bien de ensilado y proceso de ensilaje
MX2020007562A (es) Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion.
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
PE20211243A1 (es) Procedimiento y productos intermedios para la preparacion de bilastina
CL2021000950A1 (es) Anticuerpos contra el lif y usos de los mismos (divisional de la solicitud no. 201901717)
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
CL2020002598A1 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
CO2022001218A2 (es) Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso
CL2021001511A1 (es) Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CL2023001492A1 (es) Anticuerpos anti-ly6g6d y métodos de uso.